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Abstract
Background and aims—Mutations in the 5′-nucleotidase ecto (NT5E) gene that encodes 
CD73, a nucleotidase that converts AMP to adenosine, are linked to arterial calcification. 
However, the role of purinergic receptor signaling in the pathology of intimal calcification is not 
well understood. In this study, we examined whether extracellular nucleotides acting via P2Y2 
receptor (P2Y2R) modulate arterial intimal calcification, a condition highly correlated with 
cardiovascular morbidity.
Methods—Apolipoprotein E, P2Y2R double knockout mice (ApoE−/−P2Y2R−/−) were used to 
determine the effect of P2Y2R deficiency on vascular calcification in vivo. Vascular smooth 
muscle cells (VSMC) isolated from P2Y2R−/− mice grown in high phosphate medium were used 
to assess the role of P2Y2R in the conversion of VSMC into osteoblasts. Luciferase-reporter 
assays were used to assess the effect of P2Y2R on the transcriptional activity of Runx2.
Results—P2Y2R deficiency in ApoE−/− mice caused extensive intimal calcification despite a 
significant reduction in atherosclerosis and macrophage plaque content. The ectoenzyme apyrase 
that degrades nucleoside di- and triphosphates accelerated high phosphate-induced calcium 
deposition in cultured VSMC. Expression of P2Y2R inhibits calcification in vitro inhibited the 
osteoblastic trans-differentiation of VSMC. Mechanistically, expression of P2Y2R inhibited Runx2 
transcriptional activation of an osteocalcin promoter driven luciferase reporter gene.
Conclusions—This study reveals a role for vascular P2Y2R as an inhibitor of arterial intimal 
calcification and provides a new mechanistic insight into the regulation of the osteoblastic trans-
differentiation of SMC through P2Y2R-mediated Runx2 antagonism. Given that calcification of 
atherosclerotic lesions is a significant clinical problem, activating P2Y2R may be an effective 
therapeutic approach for treatment or prevention of vascular calcification.
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Introduction
Vascular calcification is a hallmark of many diseases including atherosclerosis, type 2 
diabetes, end-stage renal disease, and is highly correlated with cardiovascular morbidity (1–
2). Arterial medial calcification occurs in the absence of inflammation, and is associated 
with chronic kidney disease (CDK) in adults (3–5). Medial calcification causes vessel 
stiffening, elevated pulse-wave velocity, and increased left ventricular (LV) load with 
hypertrophy (6–9). In contrast, intimal calcification occurs in the context of atherosclerosis 
and is associated with plaque rupture and myocardial infarction (10–12). Vascular 
calcification is an active and regulated process reminiscent of physiological bone formation 
(12). VSMC are the main cell type involved in arterial calcification, and can trans-
differentiate into an osteoblast-like cell (13–14). This phenotypic transition is characterized 
by the expression of alkaline phosphatase, type I collagen, osteocalcin and the formation of 
mineralized bone-like structures (15).
Runt-related transcription factor (Runx) 2 is a key regulator of osteoblast differentiation 
(16). Runx2-null mice are devoid of osteoblasts and lack the ability to form bone (17–18). 
Runx2 mediates osteoblast differentiation as well as mineralization in immature 
mesenchymal cells and osteoblastic cells in vitro (19–20). Runx2 is expressed in calcified 
human atherosclerotic lesions as well as in calcifying mouse aortic SMC (21–23). 
Expression of Runx2 alone does not induce VSMC calcification in vitro (24), however, 
Runx2 deficiency in VSMC has been shown to inhibit vascular calcification in vivo (25). 
Given the pivotal role of Runx2 in SMC calcification, identifying factors that regulate this 
transcription factor may lead to new medical therapies to prevent or treat cardiovascular 
calcification.
A study of idiopathic infantile arterial calcification first led to the hypothesis that the 
purinergic signaling may play a role in the pathogenesis of vascular calcification (26). This 
autosomal recessive disease is caused by a mutation in the ectonucleotide pyrophosphatase-
phosphodiesterase 1 gene (ENPP1) that catalyzes the hydrolysis of pyrophosphate and 
phosphodiester bonds in nucleotide triphosphates and oligonucleotides, respectively, to 
generate nucleoside 5′-monophosphates. In addition, homozygous nonsense mutations in 
the 5′-nucleotidase ecto (NT5E) gene that encodes CD73, a nucleotidase that converts AMP 
to adenosine, have been linked to symptomatic arterial and joint calcifications (27). 
Together, these observations suggest a role for the AMP/adenosine metabolic pathway in 
inhibiting ectopic tissue calcification. Indeed, increased cAMP signaling synergizes with 
elevated extracellular inorganic phosphate (Pi) to induce calcification of vascular SMC (28). 
However, the role of purinergic receptor signaling in the pathogenesis of vascular 
calcification, particularly in the setting of atherosclerosis, is not understood.
The P2Y2 is expressed in vascular cells and its activation mediates inflammatory responses 
that contribute to intimal hyperplasia in response to injury (29–31). We recently showed that 
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P2Y2R deletion prevents fatty-streaks formation in ApoE-null mice (32). In the present 
study, we examined the effects of P2Y2R deletion on arterial intimal calcification during 
atherosclerosis. We utilized the ApoE knockout mouse model of atherosclerosis which 
develops spontaneous atherosclerosis without dietary manipulations (33). By crossing ApoE 
knockout mice with P2Y2R knockout mice, we show that although loss of P2Y2R attenuates 
atherosclerotic plaque development, it leads to extensive calcification of the atherosclerotic 
lesions. In vitro, high Pi induced-calcium deposition in VSMC and expression of stage-
specific osteoblast markers were exacerbated in the absence of P2Y2R. Finally, we 
demonstrated that P2Y2R prevents the osteoblastic trans-differentiation of VSMC by 
inhibiting Runx2 transcriptional activity. Our findings reveal a novel role of P2Y2R in the 
control of vascular calcification. Therefore, targeting P2Y2R signals in VSMC may 
represent a novel strategy for therapies targeting vascular calcification.
Materials and methods
Animals
Animal protocols were approved by the Animal Care and Use Committee of Indiana 
University and the procedures followed were in accordance with institutional guidelines. 
C57BL/6J, ApoE−/− and P2Y2R−/− mice were purchased from Jackson laboratory. P2Y2R−/− 
mice were bred to the ApoE−/− background to generate ApoE−/−/P2Y2R−/− mice. All of 
these mice are on a C57BL/6J background. All animals were fed a standard chow diet. Only 
males were used in experimental groups.
Analysis of atherosclerotic lesions in the aortic root
Mouse hearts were perfused, fixed in 4% paraformaldehyde and embedded in paraffin. Five-
micrometer sections at 50-μm intervals were stained with Masson’s trichrome for lesion area 
measurement and morphometric analysis as described in our previous studies (32). 
Apoptosis was assessed by TUNEL (Tdt-mediated dUTP nick end labeling) method using 
the TACS 2 TdT in situ apoptosis detection kit (Trevigen). For the quantification of plaque 
necrosis, aortic root lesions were stained with hematoxylin/eosin. Necrotic areas were 
identified as large non-stained areas with a 3,000-μm2 threshold, thus excluding very small 
clear areas, and quantified as previously described (34).
In situ detection of calcification
Intimal calcification was detected by performing Von Kossa staining on tissue sections. Von 
Kossa-stained sections were then counterstained for hematoxylin and eosin. Von Kossa 
reactivity was quantified and expressed as a percentage of Von Kossa positive area divided 
by total lesion area.
Tissue and cell quantification of calcium
Aortic arch specimens from mice were lyophilized to a constant weight. The calcium 
extracted from lyophilized tissue with 0.6 N HCl at 37°C for 48 hours was measured by a 
colorimetric assay using the o-cresolphsthalein complexone kit (calcium diagnostic kit; 
Sigma-Aldrich). The amount of calcium was normalized to the tissue dry weight. Calcium 
content in cultured VSMC was determined using a similar procedure as described above, 
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and expressed as micrograms of calcium per milligram of cellular protein. Protein content 
was measured using the bicinchoninic acid assay protein assay kit (Thermo Scientific).
Immunohistochemistry
Immunohistochemical staining was performed by the labeled streptavidin biotin method. 
Monoclonal anti-smooth muscle α-actin antibody (clone 1A4, Sigma, 1/1000 dilution) was 
used to detect smooth muscle cells. Macrophages were identified by immunostaining with a 
rat anti-mouse Mac-3 monoclonal antibody (M3/84, 550292, BD PharMingen, San Diego, 
CA; 1/100 dilution).
VSMC calcification assay
Aortic samples were collected from C57BL/6 and P2Y2R−/− mice and VSMC were isolated 
using the explant technique as described in our previous studies (34). SMC were seeded in 
growth medium at a density of 1.5 × 104/cm2 in multi-well plates. Cells were grown to 
confluence and incubated with calcification medium containing NaH2PO4 and Na2HPO4 at 
pH 7, to a final concentration of 3 mM phosphate. VSMC were incubated for up to 14 days 
in 95% air/5% CO2 and medium was changed every four days. Retroviral transduction of 
DNA construct into VSMC was performed as described in our previous studies (35).
Alizarin Red S staining
Cells were incubated in 10%-PFA for 10 minutes then rinsed with distilled water and 
dehydrated to 70% alcohol. Cells were stained with 2% Alizarin Red S solution for 5 
minutes then blotted dry. The slides were then dehydrated in acetone and 1:1 acetone-xylene 
solution, cleared in xylene, and mounted using a synthetic mounting medium.
Luciferase reporter assays
Cells were transfected with firefly luciferase reporter 6×OSE2-Luc plus Renilla luciferase 
reporter pRL-TK. At 48 hours after transfection, cells were harvested and firefly and Renilla 
luciferase activities in cell lysates were measured using a dual luciferase kit (Promega). 
Renilla luciferase activities in cells were used as internal control.
Gene expression analysis
Quantitative polymerase chain reaction (qPCR) was performed as previously described (36). 
Total RNA was extracted from VSMC lysed in TRIzol reagent (Invitrogen), using an 
RNeasy mini kit and treated with DNase I (Qiagen). High quality RNA was extracted (0.5 
μg/sample was used for synthesis of single-strand cDNA with Superscript II (Invitrogen). 
Syber green based real time PCR was conducted with 45 ng of cDNA using an ABI Prism 
7900HT PCR machine (Applied Biosystems). The following primers (Integrated DNA 
Technologies) were used for Runx2: forward 5′-ACC ATA ACA GTC TTC ACA AAT 
CCT-3′, and reverse: 5′-CAG GCG ATC AGA GAA CAA ACT A-3′. The primers for 
osteocalcin were as follows: forward 5′-CTGACCTCACAGATGCCAAG-3′, and reverse: 
5′-GTAGCGCCGGAGTCTGTTC-3′. GAPDH primers were used as internal control. The 
forward GAPDH primer was: 5′-GGT GGC AGA GGC CTT TG-3′. The reverse GAPDH 
primer was: 5′-TGC CCA TTT AGC ATC TCC TT-3′.
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Statistical analysis
Data are expressed as means ± SEM. Differences in data between groups were compared 
with Student’s paired 2-tailed t test or 1-way ANOVA where appropriate. A p value less than 
0.05 was considered statistically significant.
Results
P2Y2 receptor deficiency promotes calcification of atherosclerotic lesions
We assessed the effects of P2Y2R deletion on arterial calcification in ApoE−/− mice 
maintained on a standard mouse chow diet for 30 weeks. Strikingly, despite a significant 
decrease in atherosclerotic lesion area compared to ApoE−/− mice (p<0.01; Fig. 1A and B), 
ApoE−/−/P2Y2R−/− mice (15 out of 15 mice) exhibited extensive intimal calcification 
covering more than 10% of the plaque area (p<0.001; Fig. 1C–E). Micro-calcification in the 
form of spotty or granular calcium deposits was also observed in ApoE−/−/P2Y2R−/− mice 
(Fig. 1C). In contrast, large areas of calcification were absent from ApoE−/− lesions (Fig. 
1C), and only 1 out of 15 ApoE−/− mice exhibited very few granular calcium deposits. 
Notably, no calcification was observed in the media layer in either genotype. Fig. 1C shows 
a typical lesion in the aortic root, with extensive calcification in close proximity of the 
endothelium. The amount of extractable calcium that was deposited in the aortic root in 
P2Y2R−/−/ApoE−/− mice was 10-fold greater compared to that of ApoE−/− mice (Fig. 1D). 
The calcified area occupied about 13% of the total lesion area (Fig. 1E). Vascular 
calcification observed in P2Y2R−/−/ApoE−/− mice was not due to an increase in plasma 
cholesterol since P2Y2R-deficiency did not alter total plasma cholesterol in ApoE−/− mice 
(Table 1). These data demonstrate that absence of P2Y2R result in early calcification of 
atherosclerotic lesions in ApoE−/− mice.
P2Y2R deficiency reduces plaque cellularity
P2Y2R deficiency led to other differences in intimal plaque composition as well. The 
increased intimal calcification attributable to the loss of the P2Y2R gene correlated with a 
sharp reduction in the total plaque area occupied by Mac-3 positive macrophages (p<0.001, 
Fig. 2A) and a significant decrease in SMC content (p<0.001; Fig. 2B). Consequently, 
plaque cellularity (Fig. 3A) was decreased in lesions observed in P2Y2R−/−/ApoE−/− mice. 
Analysis of lesions for acellular/necrotic areas revealed a significant increase in plaque 
necrosis in the ApoE−/−/P2Y2R−/− lesions (p<0.001; Fig. 3B). We next examined if the 
increased necrosis in ApoE−/−/P2Y2R−/− lesions was due to an increase in cell apoptosis. As 
shown in Fig. 3C, apoptosis as measured by TUNEL-positive cells was 40% (p<0.001) 
higher in the ApoE−/−/P2Y2R−/− lesions. The formation of plaques with large necrotic/
apoptotic cores is followed by conversion to highly fibrotic nodules, and many of the cells 
within the nodules express markers of chondrocytes and osteoblasts (37). Notably, cells 
within the calcified areas in the ApoE−/−/P2Y2R−/− lesions exhibited chondrocyte 
appearance and features such as abundant collagen fibers and proteoglycans reacting with 
the hematoxylin counterstaining (Fig. 3D),
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Expression of P2Y2 receptor inhibits VSMC calcification in vitro
As described previously by others (38), we confirmed that high Pi induces a significant 
increase in VSMC calcium deposition, evident after 14 days in culture as compared to cells 
cultured in control medium (Fig. 4A). Notably, adding an enzyme that degrades nucleoside 
di- and triphosphates (potato apyrase grade III, 0.1 unit/ml) greatly accelerated SMC 
calcification such that high levels of calcium content were measurable by 7 days of culture 
(Fig. 4B), suggesting that nucleotides released by VSMC inhibit calcification. P2Y2R 
deficiency in VSMC significantly increased high Pi-induced calcification as demonstrated 
by a sharp increase in the amount of incorporated calcium (p<0.001) compared to VSMC 
from WT mice (Fig. 5A; p<0.001) after 7 days of culture. Interestingly, the extent of 
calcification in P2Y2−/− SMC was similar to cultures lacking nucleoside di- and 
triphosphates (Fig. 5A compared to Fig. 4B).
P2Y2 receptor inhibits the osteogenic trans-differentiation of VSMC
Calcifying VSMC adopt an osteoblast-like phenotype, including expression of osteoblast 
markers (25). Therefore, we measured the expression of the stage-specific osteoblast 
markers Runx2 and osteocalcin in VSMC from WT or P2Y2R−/− mice cultured in high Pi 
medium (Fig. 5B). Both osteoblast markers were expressed at significantly higher levels in 
P2Y2R−/− VSMC, suggesting that the absence of P2Y2R sensitizes them to calcification 
promoting conditions. Conversely, rescue of P2Y2R expression in knockout VSMC (via 
retroviral transduction of full-length WT mouse P2Y2R into P2Y2R−/− cells) decreased 
osteoblast-specific gene expression and total calcium content to levels comparable with WT 
(Fig. 5C and D). These results demonstrate that P2Y2R in VSMC is required to inhibit 
osteogenic trans-differentiation.
P2Y2 receptor represses Runx2 transcriptional activity
As Runx2 is known to be required for VSMC calcification in vitro and in vivo (25, 39) and 
its expression was increased in P2Y2R−/− VSMC, we examined whether expression of 
P2Y2R inhibits the transcriptional activity of Runx2. Overexpression of Runx2 increased the 
activity of an OC promoter driven luciferase reporter gene (40) in P2Y2R-deficient VSMC 
(Fig. 6). However, this Runx2-induced OC promoter activity was significantly attenuated in 
P2Y2R-deficient VSMC transduced with WT P2Y2R (Fig. 6). These data clearly indicate 
that P2Y2R regulates the osteogenic trans-differentiation of VSMC through Runx2 
antagonism.
Discussion
The main finding of this study supports a dual role for P2Y2 receptor as a mediator of 
atherosclerosis but an inhibitor of arterial intimal calcification. P2Y2R deficiency leads to 
reduced atherosclerotic lesion sizes, increased plaque necrosis with extensive calcification. 
Furthermore, loss of P2Y2R accelerates in vitro calcification and the osteoblastic trans-
differentiation of VSMC. Mechanistically, P2Y2R acts as a negative regulator of Runx2 
transcriptional activity.
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Intimal calcification is apparent in normal chow fed ApoE−/− mice at around 45 weeks of 
age, where small deposits of hydroxyapatite are observed (37). Surprisingly, calcium 
deposits are apparent in ApoE−/−/P2Y2R−/− mice at high frequency, as early as 30 weeks of 
age, indicating that absence P2Y2R accelerates intimal calcification. The calcified lesions 
were associated with decrease cellularity that is associated with a significant reduction in 
both macrophage and VSMC content of the plaques. The decrease in lesion cellularity 
observed in ApoE−/−/P2Y2R−/− mice was in part due to increased cell apoptosis.
Several factors may account for the increased calcification of the lesions in the ApoE−/− 
mice in the absence of P2Y2R. Increased circulating LDL and decreased HDL have been 
shown to increase plaque burden and coronary artery calcification (42). However, since 
P2Y2R deficiency does not alter plasma lipid content in the ApoE−/− mice (Table 1), this 
mechanism likely does not account for the increased calcification in these mice. The 
observation of bone-like regions within the lesions in P2Y2R−/−/ApoE−/− mice suggests that 
lack of P2Y2R stimulates an active process similar to bone formation in the lesions.
Depending on the type of calcium deposition, intimal calcification may either promote the 
formation of rupture-prone lesions or stabilize the plaque (43). Our data indicate that 
P2Y2R-deficiency drives the formation of both spotty calcium deposits (micro-calcification) 
and large calcified areas (macro-calcification). Micro-calcification which induces further 
inflammation is associated with unstable plaques while macro-calcification favors plaque 
stabilization (43). It is possible that the large areas of calcium deposits in lesions from 
ApoE−/−/P2Y2R−/− mice represent an adaptive mechanism to counter the initial detrimental 
effects caused by small granular calcium deposits. The increased stability associated with 
large calcium deposits would be consistent with increased plaque stability resulting from the 
significantly reduced macrophage content in lesions from ApoE−/−/P2Y2R−/− mice. This 
reduction in plaque macrophage content was also correlated with the presence of 
chondrocyte-like cells that are often seen in stabilized plaques (37).
Osteogenic trans-differentiation of VSMC is known to contribute directly to the 
pathogenesis of atherosclerotic calcification (25). Our data show that extracellular 
nucleotides act as inhibitors of VSMC calcification in vitro. Indeed, the enzyme potato 
apyrase that degrades nucleoside di- and triphosphates accelerated VSMC calcification 
under an osteogenic environment. The role of nucleotides in vascular calcification has been 
largely attributed to inorganic pyrophosphate. Genetic studies have shown the important 
roles for inorganic pyrophosphate (PPi) as inhibitors of vascular mineralization. Deficiency 
in the mineralization inhibitor PPi, that arises from genetic disruption of the murine 
ectoezyme NPP1 (ectonucleotide pyrophosphatase/phosphodiesterase I), causes arterial 
calcification (26). In addition, PPi deficiency due to NPP1 loss-of-function mutations is 
associated with a rare congenital disorder characterized by generalized arterial calcification 
in infants (27). The present study identifies an alternative and robust pathway by which 
extracellular nucleotides acting through P2Y2R inhibit VSMC calcification. Using loss-of-
function and gain-of-function experiments, we unequivocally established that P2Y2R is a 
powerful inhibitor of VSMC calcification. Indeed, we demonstrated that loss of P2Y2R 
accelerated high phosphate-induced calcium deposition in VSMC. Furthermore, retroviral 
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transduction of full length wild-type P2Y2R into P2Y2R−/− VSMC reduced calcium 
deposition to levels comparable with those observed in VSMC from WT mice.
Mechanistically, our studies demonstrate that P2Y2R mediated inhibition of VSMC 
calcification at least in part through repression of Runx2 transcriptional activity. Runx 
proteins are targeted to gene regulatory micro-environments within the nucleus, via a 
specific sub-nuclear targeting signal (44). However, the mechanisms that shuttle Runx2 
between the cytoplasm and the nucleus are poorly understood. It was reported that when 
endogenous Runx2 associates with stabilized microtubules it is held in the cytoplasm and 
that the Runx2 amino terminus mediates the microtubule association through the alpha/beta 
tubulin subunits (45) Thus, it is possible that P2Y2R-mediated microtubule/actin 
organization regulates Runx2 trafficking between the cytoplasm and the nucleus, a process 
that directly affects Runx2 transcriptional activity.
In conclusion, this study reveals a previously unknown function of P2Y2R in vascular 
calcification, which is distinct from deficits in the mineralization inhibitor inorganic 
pyrophosphate. Our findings provide a new mechanistic insight into the regulation of the 
osteoblastic trans-differentiation of VSMC by a nucleotide receptor, through Runx2 
antagonism. Given that calcification of atherosclerotic lesions is a highly regulated 
pathological process potentially subject to intervention, P2Y2R may be targeted for the 
treatment or prevention of vascular calcification.
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Abbreviations
CDK chronic kidney disease
ENPP1 ectonucleotide pyrophosphatase-phosphodiesterase 1
P2Y2R P2Y2 nucleotide receptor
Runx2 Runt related transcription factor-2
TRAP tartrate-resistant acid phosphatase
VCAM-1 vascular cell adhesion molecule-1
SMC smooth muscle cells
References
1. Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis 
patients. Clin Nephrol. 2000; 54:318–324. [PubMed: 11076108] 
2. Zhu D, Mackenzie NCW, Farquharson C, et al. Mechanisms and clinical consequences of vascular 
calcification. Front Endocrinol. 2012; 3:95.
Qian et al. Page 8
Atherosclerosis. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
3. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield 
J, Rees L, Shanahan CM. Dialysis accelerates medial vascular calcification in part by triggering 
smooth muscle cell apoptosis. Circulation. 2008; 118:1748–1757. [PubMed: 18838561] 
4. Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, Ketteler M, Levin A, 
Massy Z, McCarron DA, Raggi P, Shanahan CM, Yorioka N. Vascular calcification in chronic 
kidney disease. American journal of kidney diseases. 2004; 43:572–579. [PubMed: 14981617] 
5. Moorthi RN, Moe SM. CKD-mineral and bone disorder: core curriculum. Am J KidneyDis. 2011; 
58:1022–1036.
6. Guerin AP, Pannier B, Metivier F, Marchais SJ, London GM. Assessment and significance of arterial 
stiffness in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2008; 17:635–641. 
[PubMed: 19031658] 
7. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in 
end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 
2003; 18:1731–1740. [PubMed: 12937218] 
8. Kelly RP, Tunin R, Kass DA. Effect of reduced aortic compliance on cardiac efficiency and 
contractile function of in situ canine left ventricle. Circ Res. 1992; 71:490–502. [PubMed: 1386792] 
9. Niederhoffer N, Lartaud-Idjouadiene I, Giummelly P, Duvivier C, Peslin R, Atkinson J. 
Calcification of medial elastic fibers and aortic elasticity. Hypertension. 1997; 29:999–1006. 
[PubMed: 9095090] 
10. Beadenkopf WG, Daoud AS, Love BM. Calcification in the coronary arteries and its relationship to 
arteriosclerosis and myocardial infarction. Am J Roentgenol Radium Ther Nucl Med. 1964; 
92:865–887.
11. Kelly-Arnold A, Maldonado N, Laudier D, Aikawa E, Cardoso L, Weinbaum S. Revised 
microcalcification hypothesis for fibrous cap rupture in human coronary arteries. Proc Natl Acad 
Sci. 2013; 110:10741–10746. [PubMed: 23733926] 
12. Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, Nakamura Y, Yamashita 
H, Yamagishi H, Takeuchi K, Naruko T, Haze K, Becker AE, Yoshikawa J, Ueda M. Spotty 
calcification typifies the culprit plaque in patients with acute myocardial infarction: an 
intravascular ultrasound study. Circulation. 2004; 110:3424–3429. [PubMed: 15557374] 
13. Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by 
triggering smooth muscle cell apoptosis. Circulation. 2008; 118:1748–1757. [PubMed: 18838561] 
14. Zhu D, Mackenzie NC, Millan JL, et al. The appearance and modulation of osteocyte marker 
expression during calcification of vascular smooth muscle cells. PloS ONE. 2011; 6:e19595. 
[PubMed: 21611184] 
15. Collin-Osdoby P. Circ Res. 2004; 95:1046–1057. [PubMed: 15564564] 
16. Schroeder TM, Jensen ED, Westendorf JJ. Runx2: a master organizer of gene transcription in 
developing and maturing osteoblasts. Birth Defects Res C Embryo Today. 2005; 75:213–225. 
[PubMed: 16187316] 
17. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao 
YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. Targeted disruption of 
Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. 
Cell. 1997; 89:755–764. [PubMed: 9182763] 
18. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington 
RS, Mundlos S, Olsen BR, Selby PB, Owen MJ. Cbfa1, a candidate gene for cleidocranial 
dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997; 
89:765–771. [PubMed: 9182764] 
19. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: atranscriptional activator of 
osteoblast differentiation. Cell. 1997; 89:747–754. [PubMed: 9182762] 
20. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS. 
Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit 
Rev Eukaryot Gene Expr. 2004; 14:1–41. [PubMed: 15104525] 
21. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R. 
Multimodality Molecular Imaging Identifies Proteolytic and Osteogenic Activities in Early Aortic 
Valve Disease. Circulation. 2007; 115:377–386. [PubMed: 17224478] 
Qian et al. Page 9
Atherosclerosis. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
22. Engelse MA, Neele JM, Bronckers AL, Pannekoek H, de Vries CJ. Vascular calcification: 
expression patterns of the osteoblast-specific gene core binding factor α-1 and the protective factor 
matrix gla protein in human atherogenesis. Cardiovasc Res. 2001; 52:281–289. [PubMed: 
11684076] 
23. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/Chondrocytic 
Transcription Factors and Their Target Genes Exhibit Distinct Patterns of Expression in Human 
Arterial Calcification. Arterioscler Thromb Vasc Biol. 2003; 23:489–494. [PubMed: 12615658] 
24. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, McDonald JM, Chen Y. 
Oxidative stress induces vascular calcification through modulation of the osteogenic transcription 
factor Runx2 by AKT signaling. J Biol Chem. 2008; 283:15319. [PubMed: 18378684] 
25. Sun Y, Byon CH, Yuan K, Chen J, Mao X, Heath JM, Javed A, Zhang K, Anderson PG, Chen Y. 
Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res. 2012; 
111(5):543–52. [PubMed: 22773442] 
26. Rutsch F, Ruf N, Vaingankar S, et al. Mutations in ENPP1 are associated with ‘idiopathic’ infantile 
arterial calcification. Nat Genet. 2003; 34:379–81. [PubMed: 12881724] 
27. St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, Carlson-Donohoe H, 
Lederman RJ, Chen MY, Yang D, Siegenthaler MP, Arduino C, Mancini C, Stanescu HC, Zdebik 
AA, Chaganti RK, Nussbaum RL, Kleta R, Gahl WA, Boehm M. NT5E Mutations and Arterial 
Calcifications. N Engl J Med. 2011; 364(5):432–442. [PubMed: 21288095] 
28. Prosdocimo DA, Wyler SC, Romani AM, O’Neill WC, Dubyak GA. Regulation of vascular 
smooth muscle cell calcification by extracellular pyrophosphate homeostasis: synergistic 
modulation by cyclic AMP and hyperphosphatemia. Am J Physiol Cell Physiol. 2010; 
298(3):C702–C713. [PubMed: 20018951] 
29. Seye CI, Yu N, Jain R, Kong Q, Minor T, Newton J, Erb L, Gonzalez FA, Weisman GA. The P2Y2 
nucleotide receptor mediates UTP-induced vascular cell adhesion molecule-1 expression in 
coronary artery endothelial cells. J Biol Chem. 2003; 278:24960–24965. [PubMed: 12714597] 
30. Seye CI, Yu N, Gonzalez FA, Erb L, Weisman GA. The P2Y2 Nucleotide Receptor Mediates 
Vascular Cell Adhesion Molecule-1 Expression through Interaction with VEGF Receptor-2 (KDR/
Flk-1). J Biol Chem. 2004; 279:35679–35686. [PubMed: 15175347] 
31. Seye CI, Kong Q, Erb L, Garrad RC, Krugh B, Wang M, Turner JT, Sturek M, Gonzalez FA, 
Weisman GA. Functional P2Y2 nucleotide receptors mediate uridine 5′-triphosphate-induced 
intimal hyperplasia in collared rabbit carotid arteries. Circulation. 2002; 106:2720–2726. 
[PubMed: 12438299] 
32. Qian, Shaomin, Hoggatt, April, Jones-Hall, Yava L., Ware, Carl F., Herring, Paul, Seye, Cheikh I. 
Deletion of P2Y2 Receptor Reveals a Role for Lymphotoxin-α in Fatty Streak Formation. Vascul 
Pharmacol. 2016; 85:11–20. [PubMed: 27355755] 
33. Van Vlijmen BJ, et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein 
E3-Leiden transgenic mice. J Clin Invest. 1994; 93:1403–10. [PubMed: 8163645] Westenfeld R, 
Schäfer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, Jahnen-Dechent W. Fetuin-A 
(AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. 
Nephrol Dial Transplant. 2007; 22(6):1537–46. [PubMed: 17389622] 
34. Feng B, Zhang D, Kuriakose G, Devlin CM, Kockx M, Tabas I, Niemann-Pick C. Heterozygosity 
confers resistance to lesional necrosis and macrophage apoptosis in murine atherosclerosis. Proc 
Natl Acad Sci U S A. 2003; 100:10423–10428. [PubMed: 12923293] 
35. Yu N, Erb L, Shivaji R, Weisman GA, Seye CI. Binding of the P2Y2 nucleotide receptor to filamin 
A regulates migration of vascular smooth muscle cells. Circ Res. 2008; 102:581–588. [PubMed: 
18202316] 
36. Seye CI, Agca Y, Agca C, Derbigny W. P2Y2 receptor-mediated lymphotoxin-α (LTA) secretion 
regulates intercellular cell adhesion molecule (ICAM)-1 expression in vascular smooth muscle 
cells. J Biol Chem. 2012; 287:10535–10543. [PubMed: 22298782] 
37. Rattazzi M, Bennett BJ, Bea F, Kirk EA, Ricks JL, Speer M, Schwartz SM, Giachelli CM, 
Rosenfeld ME. Calcification of advanced atherosclerotic lesions in the innominate arteries of 
ApoE-deficient mice: potential role of chondrocyte-like cells. Arterioscler Thromb Vasc Biol. 
2005; 25:1420–1425. [PubMed: 15845913] 
Qian et al. Page 10
Atherosclerosis. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
38. Speer MY, Chien YC, Quan M, Yang HY, Vali H, McKee MD, Giachelli CM. Smooth muscle cells 
deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc Res. 
2005; 66(2):324–33. [PubMed: 15820201] 
39. Lin ME, Chen T, Leaf EM, Speer MY, Giachelli CM. Runx2 Expression in Smooth Muscle Cells Is 
Required for Arterial Medial Calcification in Mice. Am J Pathol. 2015; 185(7):1958–1969. 
[PubMed: 25987250] 
40. Zhang H, Pan Y, Zheng L, Choe C, Lindgren B, Jensen ED, Westendorf JJ, Cheng L, Huang H. 
FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. 
Cancer Res. 2011; 71(9):3257–3267. [PubMed: 21505104] 
41. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, 
Ostankovich M, Sharma P, Lysiak JJ, Harden TK, Leitinger N, Ravichandran KS. Nucleotides 
released by apoptotic cells act as a find me signal to promote phagocytic clearanc. Nature. 2009; 
461(7261):282–286. [PubMed: 19741708] 
42. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, 
Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG. Influence of lipid-
lowering therapy on the progression of coronary artery calcification: a prospective evaluation. 
Circulation. 2002; 106(9):1077–1082. [PubMed: 12196332] 
43. Pugliese G, Iacobini C, Blasetti Fantauzzi C, Menini S. The dark and bright side of atherosclerotic 
calcification. Atherosclerosis. 2015; 238(2):220–30. [PubMed: 25528431] 
44. Zaidi, Sayyed K., Young, Daniel W., Choi, Je-Yong, Pratap, Jitesh, Javed, Amjad, Montecino, 
Martin, Stein, Janet L., van Wijnen, Andre J., Lian, Jane B., Stein, Gary S. The dynamic 
organization of gene-regulatory machinery in nuclear microenvironments. EMBO Rep. 2005; 6(2):
128–133. [PubMed: 15689940] 
45. D’Addario M, Arora PD, Ellen RP, McCulloch CA. Regulation of tension-induced 
mechanotranscriptional signals by the microtubule network in fibroblasts. J Biol Chem. 2003; 
278(52):53090–53097. [PubMed: 14561736] 
46. Pockwinse SM, Rajgopal A, Young DW, Mujeeb KA, Nickerson J, Javed A, Redick S, Lian JB, 
van Wijnen AJ, Stein JL, Stein GS, Doxsey SJ. Microtubule-dependent nuclear-cytoplasmic 
shuttling of Runx2. J Cell Physiol. 2006; 206(2):354–362. [PubMed: 16110492] 
Qian et al. Page 11
Atherosclerosis. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
• P2Y2 receptor deficiency in ApoE−/− mice reduces atherosclerosis
• Loss of P2Y2 receptor accelerates arterial intimal calcification in ApoE−/− 
mice
• Expression of P2Y2 receptor inhibits high phosphate-induced smooth muscle 
cell calcification
• P2Y2 receptor negatively regulates Runx2 transcriptional activity in smooth 
muscle cells.
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Fig. 1. P2Y2 receptor deficiency reduces atherosclerosis and increases calcification of 
atherosclerotic lesions
(A) Light micrographs of representative Masson’s trichrome stained aortic root lesions from 
ApoE−/− and ApoE−/−/P2Y2R−/− mice, showing atherosclerotic lesion (area between yellow 
and red lines) as well as collagen and muscle fibers in the lesions. (B) Quantitative analysis 
of lesions in the aortic sinus. Data represent the mean ± SEM lesion area for 5 consecutive 
sections in each of the 12 mice examined for each genotype. (*p<0.001). Scale represents 
100 μm. Arrows indicate lesions. (C) Representative images of sections stained with Von 
Kossa to detect calcification. Areas in insert have been magnified. Arrows indicate spotty 
calcium deposits. Scale bar = 100μm. (D) Quantification of the sinus aortic calcium content 
expressed as mmol/g of dried weight and (E) calcification presented as percentage of Von 
Kossa-positively stained areas in the total aortic lesion. Quantification was done using 5 
cross sections in each of the 12 ApoE−/− mice and 12 ApoE−/−/P2Y2R−/− mice. Bar values 
are means ± SEM, *p<0.001.
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Fig. 2. P2Y2 receptor modulates cellular composition and cellularity of atherosclerotic lesions
(A and B) Representative images of immunohistological staining of atherosclerotic lesions 
in the aortic sinus. Adjacent sections were stained with (A) Mac-3 or (B) smooth muscle α-
actin antibodies, respectively. The percentage of Mac-3 or smooth muscle α-actin-positive 
areas in A and B was calculated by dividing the positively stained areas by the total cross-
sectional area of the lesion. Bar values are means ± SEM. Five cross sections were evaluated 
in 12 mice for each genotype. ***p<0.001. Arrows indicate the localization of the staining. 
Scale bar represents 100 μm.
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Fig. 3. Reduction of plaque cellularity in ApoE−/−/P2Y2R−/− mice
(A) Total nuclei were counted in each hematoxylin eosin-stained cross sections (n=5) from 
12 mice in each group and normalized to the area lesion. **p<0.01. Scale bar represents 100 
μm. (B) Evaluation of plaque necrosis. Representative images of aortic root sections (n=5) 
from 12 mice of each group genotype were stained with hematoxylin and eosin, and plaque 
necrosis was quantified. Necrotic areas are indicated with an asterisk. ***p<0.001. Scale bar 
represents 100 μm. (C) TUNEL-positive nuclei were quantified on lesions from 12 ApoE−/− 
and 13 ApoE−/−/P2Y2R−/− mice.***p<0.001. (D) High magnification of aortic root cross 
section from ApoE−/−/P2Y2R−/− mice showing chondrocyte-like cells (asterisk) within large 
areas of calcification. Scale bar represents 25 μm.
Qian et al. Page 15
Atherosclerosis. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. P2Y2R deficiency in VSMC enhances high phosphate-induced calcification in VSMC
(A) Wild-type (WT) and P2Y2R−/− VSMC were incubated in high phosphate (High Pi) or 
control medium (Low Pi) for 7 or 14 days and stained with alizarin red. Calcium deposition 
was quantified. Results are presented as mean ± SEM. *p<0. 05; ***p < 0.001; n=4 
independent experiments. (B) VSMC were cultured in high or low phosphate medium in the 
absence or presence of apyrase. Calcium deposition was quantified as in (A). Data represent 
mean ± SEM of 5 independent experiments. NS= Not significant; ***p < 0.001. Scale bar 
=100 μm.
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Fig. 5. Expression of P2Y2 receptor prevents smooth muscle cell calcification in vitro
(A) Wild-type (WT) and P2Y2R−/− VSMC were incubated in high phosphate (High Pi) or 
control medium (Low Pi) for 7 days and stained with alizarin red. Scale bar =100μm. (B) 
Calcium deposition in VSMC was quantified as in Fig. 4. Fold changes in the mRNA 
expression of osteogenic markers Runx2 and osteocalcin relative to that seen in WT cells are 
shown in bar graphs. Results are presented as mean ± SEM. ***p < 0.001; n=4 independent 
experiments. Transduction of WT P2Y2R into P2Y2R−/− inhibits (C) calcium deposition as 
well as (D) relative mRNA levels for Runx2 and osteocalcin. ***p < 0.001; n=3 independent 
experiments; NS= not significant.
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Fig. 6. P2Y2R inhibits Runx2-activation of the osteocalcin promoter
P2Y2R-null VSMC were transfected with an osteocalcin promoter luciferase reporter gene, 
an internal control pRL-TK plasmid, a Runx2 expression plasmid, and a full length P2Y2R 
expression plasmid as indicated. Lysates were harvested 48 h after transfection and were 
normalized to the expression of the pRL-TK plasmid. Results are presented as the mean ± 
SD of triplicates of cells and are representative of three independent experiments. 
***p<0.001.
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Table 1
Body weight and plasma lipid analysis in standard chow-fed ApoE−/− and ApoE−/−/P2Y2R−/− mice.
Week 30 (n=11) ApoE−/− ApoE−/−/P2Y2R−/−
Body weight (g) 37.2.5 ± 2 36 ± 1.8
Total cholesterol (mg/dl) 459 ± 35 452 ± 29
Triglycerides (md/dl) 74 ± 9 76 ± 7
Atherosclerosis. Author manuscript; available in PMC 2018 February 01.
